Search
SoHO
Substances of Human Origin (SoHO)
EHA has been involved in the evaluation and revision of EU legislation on human blood and blood components, from the start of process in 2016 to the presentation of the European Commission’s proposed Substances of Human…
EHA joins ESMO in calling for EU action on shortages of essential medicines
EHA joins ESMO in calling for EU action on shortages of essential medicines
The European Hematology Association (EHA) has endorsed and signed a collective Call to Action, prepared by the European Society for Medical Oncology (ESMO), on shortages of inexpensive, essential…
EHA and EMBL-EBI are launching CBTH
The Hague, May 2022 - The European Hematology Association (EHA) and the EMBL’s European Bioinformatics Institute (EMBL-EBI) are launching a new mentoring program, Computational Biology Training in Hematology (CBTH), this June.
Read moreATMPs and CAR-T: the uptake challenge
Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.
Read moreAbstract & Clinical Case Submission and Travel Grant
Abstract and clinical case procedureAbstract submission is closed
The official abstract submission closed on August 1, 2023 (23:59).
I4MDS consortium: advancing MDS treatment and understanding
The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.
Read moreAppointment of new EHA Managing Director
The Hague (Netherlands), January 16, 2023. The European Hematology Association (EHA) is pleased to welcome its new Managing Director, Ignacio Quiles Lara, who took up the post on January 9.
Read morePosition of EHA on Clinical Trials
The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.
Revision of the EU’s pharmaceutical legislation
Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- »